DLCO in PH
|Markers for PH in Scleroderma
Right Heart Catheterization
Diagnosing pulmonary hypertension in systemic scleroderma, especially in the early stages, can be difficult.
Systemic scleroderma can affect the same organs as pulmonary hypertension and symptoms such as fatigue and shortness of breath, the early symptoms of pulmonary hypertension, can also be caused by systemic scleroderma.
Systemic scleroderma symptoms can make it difficult to evaluate the progression and severity of pulmonary hypertension. The 6 minute walk test, used to assess pulmonary hypertension can be hindered or rendered impossible by fatigue, muscle weakness, contractures, musculoskeletal pain, heart and lung complications caused by systemic scleroderma.
For any queries about pulmonary hypertension secondary to systemic scleroderma please see a registered scleroderma expert. (Also see What is Scleroderma?, What is Pulmonary Hypertension?, and Scleroderma Experts)
Patients with scleroderma require 'annual screening' for pulmonary arterial hypertension. Every patient with systemic sclerosis should be screened for pulmonary arterial hypertension every year, as early recognition, referral and aggressive treatment are necessary to improve long–term outcomes, according to Virginia Steen, MD. Healio Rheumatology, 05/22/2019.
Diagnosing and managing scleroderma–related pulmonary arterial hypertension. This article describes scleroderma–related PAH and its diagnosis and management. PubMed, JAAPA, 2017 Sep;30(9):11-18.
Initially there may be no symptoms at all of pulmonary hypertension. Later, symptoms include shortness of breath, weakness, and fatigue with exertion. As it progresses, patients become very tired after only slight activity. Eventually, patients experience right-sided heart failure and death. However, the course of mild to moderate PH in scleroderma patients is still unknown, and its possible that it may persist unchanged for long periods of time.
Shortness of Breath This worrisome symptom has many acute and chronic causes. Follow this flowchart for more information about the diseases in which shortness of breath occurs. familydoctor.org.
Case Report: Multifactorial Pulmonary Hypertension in Systemic Sclerosis. We present a case of pulmonary arterial hypertension (PAH) in a patient with rapidly progressing symptoms to highlight the need for an early and thorough diagnostic workup. PubMed, Cureus.
Use of red cell distribution width (RDW) in a population at high risk for pulmonary hypertension (PH). The ease of obtaining RDW as a biomarker may help detect incident PH at earlier stages among patients who are at high risk for development of PH. PubMed, Respir Med, 2019 Apr;150:131-135.
Pulmonary arterial hypertension (PAH) in scleroderma (SSc): care gaps in screening. Screening for PAH in SSc allows for earlier detection and treatment that prolongs survival and improves symptoms. BioMed Central, Arthritis Research & Therapy, 2017 19:128.
Value of lung diffusing capacity for nitric oxide in systemic sclerosis. Decreased DLCO in the absence of lung restriction does not allow to suspect pulmonary arterial hypertension without fibrosis. PubMed, Physiol Rep, 2019 Aug;7(13):e14149.
Incidence of pulmonary hypertension (PHT) in patients with systemic sclerosis (SSc) and no pulmonary symptoms: is annual echocardiographic screening necessary? The incidence of echocardiography-diagnosed PHT with SSc, and no pulmonary symptoms was low. Annual echocardiography is less beneficial among such patients; repeated echocardiography should instead be performed on those with a declining functional class. PubMed, J Clin Rheumatol.
Update of Screening and Diagnostic Modalities for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (CTD-PAH). Current screening for PAH in CTDs is centered on scleroderma and data continues to support the use of transthoracic echocardiography. PubMed, Semin Arthritis Rheum, 2019 Jun;48(6):1059-1067.
The Classification of Pulmonary Arterial Hypertension. Why does the literature sometimes refer to WHO functional class and sometimes to NYHA functional class? What is the difference? Pulmonary Hypertension News.
Interleukin-32 in Systemic Sclerosis (SS), a Potential New Biomarker for Pulmonary Arterial Hypertension (PAH). Our study suggested that sera determination of IL-32 may be a promising approach to evaluate the presence of PAH in SSc patients. PubMed, Arthritis Res Ther, 2020 Jun 1;22(1):127. (Also see Interleukins)
Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis (SSc–PAH). The combination of Midkine and Follistatin-like 3 can serve as an SSc–PAH biomarker and are potential drug targets for this rare disease population. PubMed, Arthritis Res Ther, 2018 Aug 16;20(1):185.
Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension (PAH). Plasma levels of PlGF, sVEGFR-1, TNF-α, and VEGF-D have potential in screening for SSc–associated PAH. Plasma sVEGFR-1 may be a biomarker of treatment response. PubMed, Scand J Rheumatol, 2018 Mar 12:1-6.
Anticardiolipin antibodies (aCL) are significantly associated with pulmonary arterial hypertension in systemic sclerosis (scleroderma) patients. (Also see What is Scleroderma?, Types of Scleroderma, and Antiphospholipid Syndrome)
P-wave amplitude and pulmonary artery pressure in scleroderma. P-wave amplitude analysis on the ECG may be helpful in the assessment of pulmonary hypertension in patients with scleroderma. PubMed, J Electrocardiol.
Incidence of pulmonary hypertension (PH) and determining factors in patients with systemic sclerosis (SSc). It was possible to identify manifest PH in almost 25% of patients using prospective right heart catheterisation during follow-up. PubMed, Eur Respir J, 2018 Apr 4;51(4).
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis (SSc). Our findings emphasize the need to consider right heart catheterisation in selected early SSc patients with pulmonary hypertension suspicion (PH), to clearly determine the cause of PH. PubMed, Clin Exp Rheumatol, 06/20/2017.
Determining the necessity for right heart catheterization (RHC) in pulmonary hypertension (PH) associated with connective tissue diseases (CTD) assessed by echocardiography. These findings demonstrate the necessity for RHC and differences in prognosis of PH in CTD. PubMed, Int J Rheum Dis. (Also see Connective Tissue Diseases)
Determinants of Pulmonary Arterial Hypertension (PAH) in Scleroderma. The present analysis identified pulmonary fibrosis and Raynaud's phenomenon preceding SSc skin manifestations by at least 3 years as risk factors for PAH in our scleroderma cohort. PubMed, Semin Arthritis Rheum.
Usefulness of Six-Minute Walk Test (6MWT) in Systemic Sclerosis. Recent studies suggest two alternatives to the 6MWT: maximal cardiopulmonary exercise testing and DLCO testing during effort. PubMed, Clin Exp Rheumatol, Jul-Aug 2018;36 Suppl 113(4):161-167. (Also see Diagnosis of Scleroderma Pulmonary Involvement)
Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease–associated pulmonary hypertension (CTD-PH). In patients with CTD-PH, abnormal HRR1 (defined as HRR1 of lower than 16) after the six minute walk test is a strong predictor of clinical worsening, time to clinical worsening, survival, and hospitalization. PubMed, Pulm Circ.
We have the world's best supporters! See ISN News.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: